# Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Study · id `cardio:ct-nct06712030` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06712030](<https://clinicaltrials.gov/study/NCT06712030>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06712030

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 114 participants.

## Technical summary

Registry record NCT06712030. Randomized; single masking; primary purpose treatment. Start 2025-01 (anticipated); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 114 participants (planned count; ClinicalTrials.gov record NCT06712030, source copy `cardio:ctgov-nct06712030-2024-12-02`, retrieved 2026-10-26)
- Planned start: 2025-01 (anticipated) (ClinicalTrials.gov record NCT06712030, source copy `cardio:ctgov-nct06712030-2024-12-02`, retrieved 2026-10-26)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT06712030, source copy `cardio:ctgov-nct06712030-2024-12-02`, retrieved 2026-10-26)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06712030, source copy `cardio:ctgov-nct06712030-2024-12-02`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT06712030, source copy `cardio:ctgov-nct06712030-2024-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06712030-2024-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
- Acronym: SAVA-TTR
- Condition: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Intervention (Drug): Sacubitril / Valsartan
- Lead sponsor: Puerta de Hierro University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: Puerta de Hierro University Hospital (`cardio:org-puerta-de-hierro-university-hospital`)

## Provenance

Content hash: 3404440e025219c100f1aa6a5932ae33a8cc491c6b76c14f6c7b8cb6279955c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
